Staphylokinase clot-dissolving medicine for massive pulmonary embolism in everyday care
Observes how safe and effective non-immunogenic staphylokinase is in adults with massive pulmonary embolism.
Key facts
- Who runs it
- Supergene, LLC
- Where
- Russia14 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Post-registration Trial of the Non-immunogenic Staphylokinase in Massive Pulmonary Embolism
- Status
- Recruiting
- People taking part
- 20,000 people, planned
- Started
- 1 Jun 2025
- Expected to end
- 31 Dec 2027
- Type of study
- Observational
- Treatments tested
- Non-immunogenic staphylokinasenon-immunogenic staphylokinase 15 mg as a single intravenous bolus Other Names: Fortelyzin®
- Record updated
- 6 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with massive pulmonary embolism (a large blood clot in the lungs) who get clot-dissolving treatment with non-immunogenic staphylokinase in routine care.
- Age
- 18 years and older
- Sex
- Men and women
- Disease stage
- Massive pulmonary embolism confirmed by computer tomography (CT scan). There must be at least one sign of strain or poor function of the right heart chamber, plus ongoing low blood pressure or shock. Symptoms started no more than 14 days ago.
- Earlier treatment
- People must get clot-dissolving treatment with non-immunogenic staphylokinase, 15 mg as a single injection into a vein.
Main reasons for not taking part
- High risk of bleeding, for example heavy bleeding now or within the previous 6 months, or bleeding inside the skull now or in the past
- Stroke caused by bleeding within the last 6 months, or major surgery or major injury within the previous 4 weeks
- Severe liver disease, stomach or duodenal ulcer within the last 3 months, or acute pancreatitis
- Pregnancy or breastfeeding
- Known allergy to non-immunogenic recombinant staphylokinase
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Men and women aged 18 years and older
- Verified diagnosis of massive pulmonary embolism (using computer tomography)
- Signs of overload / dysfunction of the right ventricle (at least one) in combination with persistent arterial hypotension or shock
- The time from the symptoms onset is no more than 14 days
- Thrombolysis with the non-immunogenic staphylokinase, 15 mg as a single intravenous bolus
Who cannot take part
- Increased risk of bleeding:; extensive bleeding at present or within the previous 6 months; intracranial (including subarachnoid) hemorrhage at present or in history; hemorrhagic stroke within the last 6 months; a history of diseases of the central nervous system (including neoplasms, aneurysms); intracranial or spinal surgical interventions within the last 2 months; major surgery or major trauma within the previous 4 weeks; recent puncture of an incompressible blood vessel (eg, subclavian or jugular vein); severe liver disease, including liver failure, cirrhosis, portal hypertension (including esophageal varices) and active hepatitis; confirmed gastric or duodenal ulcer within the last 3 months; neoplasm with an increased risk of bleeding; simultaneous administration of Dabigatran without prior administration of idarucizumab; arterial aneurysms, developmental defects of arteries / veins; acute pancreatitis; bacterial endocarditis, pericarditis; suspicion of aortic dissecting aneurysm; any other conditions, in the opinion of the investigator, associated with a high risk of bleeding
- Known hypersensitivity to the non-immunogenic recombinant staphylokinase
- Lactation, pregnancy
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The aim of FORPE Registry is to study the safety and efficacy of the non-immunogenic staphylokinase in patients with massive pulmonary embolism in routine clinical practice.
The group in the trial
- Non-immunogenic staphylokinase
Drug: non-immunogenic staphylokinase 15 mg as a single intravenous bolus Other Names: Fortelyzin®
Treatment: Non-immunogenic staphylokinasenon-immunogenic staphylokinase 15 mg as a single intravenous bolus Other Names: Fortelyzin®
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- An Open, Prospective, Non-interventional, Multicentre, Controlled Study of Safety and Efficacy of the Thrombolysis With the Non-immunogenic Staphylokinase in Patients With Massive Pulmonary Embolism (FORPE Registry)
- Plain-language title
- Staphylokinase clot-dissolving medicine for massive pulmonary embolism in everyday careGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 6 July 2026